Key result
Pre-treatment with 17 beta-estradiol or a specific estrogen receptor beta agonist significantly improved cardiac recovery and reduced apoptosis after ischemia/reperfusion injury in ovariectomized mice.
Why the study?
Does pre-treatment with 17β-estradiol or a specific ERβ agonist improve cardiac recovery and reduce apoptosis in ovariectomized female mice subjected to ischemia/reperfusion injury?
Does pre-treatment with 17β-estradiol or a specific ERβ agonist improve cardiac recovery and reduce apoptosis in ovariectomized female mice subjected to ischemia/reperfusion injury?
p-value: p=<0.05
Activation of ERβ by a specific agonist or 17β-estradiol improves cardiac recovery after ischemia/reperfusion injury by inhibiting apoptosis and preserving mitochondrial integrity in a female mouse model.
May support ERβ-targeted cardioprotection in estrogen-deficient states; leaves open clinical translation pending human trials.
BACKGROUND: Estrogen improves cardiac recovery after ischemia/reperfusion (I/R) by yet incompletely understood mechanisms. Mitochondria play a crucial role in I/R injury through cytochrome c-dependent apoptosis activation. We tested the hypothesis that 17β-estradiol (E2) as well as a specific ERβ agonist improve cardiac recovery through estrogen receptor (ER)β-mediated mechanisms by reducing mitochondria-induced apoptosis and preserving mitochondrial integrity. METHODS: We randomized ovariectomized C57BL/6N mice 24h before I/R to pre-treatment with E2 or a specific ERβ agonist (ERβA). Isolated hearts were perfused for 20min prior to 30min global ischemia followed by 40min reperfusion. RESULTS: Compared with controls, ERβA and E2 treated groups showed a significant improvement in cardiac recovery, i.e. an increase in left ventricular developed pressure, dP/dtmax and dP/dtmin. ERβA and E2 pre-treatment led to a significant reduction in apoptosis with decreased cytochrome c release from the mitochondria and increased mitochondrial levels of anti-apoptotic Bcl2 and ACAA2. Protein levels of mitochondrial translocase inner membrane (TIM23) and mitochondrial complex I of respiratory chain were increased by ERβA and E2 pre-treatment. Furthermore, we found a significant increase of myosin light chain 2 (MLC2) phosphorylation together with ERK1/2 activation in E2, but not in ERβA treated groups. CONCLUSIONS: Activation of ERβ is essential for the improvement of cardiac recovery after I/R through the inhibition of apoptosis and preservation of mitochondrial integrity and can be a achieved by a specific ERβ agonist. Furthermore, E2 modulates MLC2 activation after I/R independent of ERβ.
No takes yet. Share an insight, caveat, or question.
Schubert et al. (2016) studied Ischemia/reperfusion injury. 17 beta-estradiol (E2) and specific ER beta agonist (ERβA) vs. Vehicle was evaluated on Cardiac recovery (left ventricular developed pressure, dP/dtmax, dP/dtmin) (p=<0.05). Pre-treatment with 17 beta-estradiol or a specific estrogen receptor beta agonist significantly improved cardiac recovery and reduced apoptosis after ischemia/reperfusion injury in ovariectomized mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: